These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Tackling non-muscle invasive bladder cancer in the clinic. Woldu SL; Şanli Ö; Lotan Y Expert Rev Anticancer Ther; 2017 May; 17(5):467-480. PubMed ID: 28359179 [TBL] [Abstract][Full Text] [Related]
3. Bladder-preserving strategies for Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected? Sari Motlagh R; Pradere B; Mori K; Miura N; Abufaraj M; Shariat SF Curr Opin Urol; 2020 Jul; 30(4):584-593. PubMed ID: 32304379 [TBL] [Abstract][Full Text] [Related]
4. Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer. Hannouneh ZA; Hijazi A; Alsaleem AA; Hami S; Kheyrbek N; Tanous F; Khaddour K; Abbas A; Alshehabi Z Cancer Med; 2023 Dec; 12(24):21944-21968. PubMed ID: 38037752 [TBL] [Abstract][Full Text] [Related]
5. Novel anticancer therapy in BCG unresponsive non-muscle-invasive bladder cancer. Moussa M; Papatsoris AG; Dellis A; Abou Chakra M; Saad W Expert Rev Anticancer Ther; 2020 Nov; 20(11):965-983. PubMed ID: 32915676 [TBL] [Abstract][Full Text] [Related]
6. Emerging treatments for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer. Kim HS; Seo HK Investig Clin Urol; 2021 Jul; 62(4):361-377. PubMed ID: 34085791 [TBL] [Abstract][Full Text] [Related]
13. Intravesical and alternative bladder-preservation therapies in the management of non-muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin. Steinberg RL; Thomas LJ; Nepple KG Urol Oncol; 2016 Jun; 34(6):279-89. PubMed ID: 26777259 [TBL] [Abstract][Full Text] [Related]
14. Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis. Kamat AM; Lerner SP; O'Donnell M; Georgieva MV; Yang M; Inman BA; Kassouf W; Boorjian SA; Tyson MD; Kulkarni GS; Chang SS; Konety BR; Svatek RS; Balar A; Witjes JA Eur Urol Oncol; 2020 Jun; 3(3):318-340. PubMed ID: 32201133 [TBL] [Abstract][Full Text] [Related]
16. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466 [TBL] [Abstract][Full Text] [Related]
18. What to do during Bacillus Calmette-Guérin shortage? Valid strategies based on evidence. Abufaraj M; Mostafid H; Shariat SF; Babjuk M Curr Opin Urol; 2018 Nov; 28(6):570-576. PubMed ID: 30138122 [TBL] [Abstract][Full Text] [Related]
19. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer. Lamm D; Brausi M; O'Donnell MA; Witjes JA Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309 [TBL] [Abstract][Full Text] [Related]
20. Role of immunotherapy in bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer. Mukherjee N; Svatek RS; Mansour AM Urol Oncol; 2018 Mar; 36(3):103-108. PubMed ID: 29429897 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]